

S1 Table. The spectra of non-targeted mutations induced by integration of pvIT^G, pvIT^{1x8oG}, pvIT^{2x8oG}, and pvINT^{2x8oG}. ^a Underlined sequences are observed mutations. “Δ” indicates one-base deletion. del., deletion; ins., insertion. ^b “8” in the sequence indicates 8-oxoG. ^c XPA KO + pCl-XPA cells. (XLSX)

Acknowledgments

We are grateful to Dr. Toshiya Arakawa (Health Sciences University of Hokkaido) for helpful advice regarding PCR-based preparation of targeting vector containing DNA adducts. We thank Dr. Masami Yamada (National Institute of Health Sciences) for critically reading the manuscript and Dr. Katsuyoshi Horibata (National Institute of Health Sciences) for helpful discussions. We thank Enago (www.enago.jp) for English-language review.

Author Contributions

Conceived and designed the experiments: AS MH MY. Performed the experiments: AS NK YK. Analyzed the data: AS NK YK MY. Contributed reagents/materials/analysis tools: AS NK YK MY. Wrote the paper: AS MY. Established cell lines used in this study: AS NK MY MH.

References

1. Sutherland BM, Bennett PV, Sidorkina O, Laval J. Clustered DNA damages induced in isolated DNA and in human cells by low doses of ionizing radiation. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(1):103–8. PMID: [10618378](https://pubmed.ncbi.nlm.nih.gov/10618378/); PubMed Central PMCID: [PMC26623](https://pubmed.ncbi.nlm.nih.gov/PMC26623/).
2. Sutherland BM, Bennett PV, Sutherland JC, Laval J. Clustered DNA damages induced by x rays in human cells. *Radiation research*. 2002; 157(6):611–6. PMID: [12005538](https://pubmed.ncbi.nlm.nih.gov/12005538/).
3. Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. *Mutation research*. 1991; 250(1–2):3–16. PMID: [1944345](https://pubmed.ncbi.nlm.nih.gov/1944345/).
4. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. *Nature*. 1991; 349(6308):431–4. doi: [10.1038/349431a0](https://doi.org/10.1038/349431a0) PMID: [1992344](https://pubmed.ncbi.nlm.nih.gov/1992344/).
5. Nilsen H, Krokan HE. Base excision repair in a network of defence and tolerance. *Carcinogenesis*. 2001; 22(7):987–98. PMID: [11408341](https://pubmed.ncbi.nlm.nih.gov/11408341/)
6. Rosenquist TA, Zharkov DO, Grollman AP. Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. *Proceedings of the National Academy of Sciences of the United States of America*. 1997; 94(14):7429–34. PMID: [9207108](https://pubmed.ncbi.nlm.nih.gov/9207108/); PubMed Central PMCID: [PMC23838](https://pubmed.ncbi.nlm.nih.gov/PMC23838/).
7. Michaels ML, Tchou J, Grollman AP, Miller JH. A repair system for 8-oxo-7,8-dihydrodeoxyguanine. *Biochemistry*. 1992; 31(45):10964–8. PMID: [1445834](https://pubmed.ncbi.nlm.nih.gov/1445834/).
8. Jiang Y, Wang Y, Wang Y. In vitro replication and repair studies of tandem lesions containing neighboring thymidine glycol and 8-oxo-7,8-dihydro-2'-deoxyguanosine. *Chemical research in toxicology*. 2009; 22(3):574–83. doi: [10.1021/tx8003449](https://doi.org/10.1021/tx8003449) PMID: [19193190](https://pubmed.ncbi.nlm.nih.gov/19193190/); PubMed Central PMCID: [PMC2765499](https://pubmed.ncbi.nlm.nih.gov/PMC2765499/).
9. Parsons JL, Zharkov DO, Dianov GL. NEIL1 excises 3' end proximal oxidative DNA lesions resistant to cleavage by NTH1 and OGG1. *Nucleic acids research*. 2005; 33(15):4849–56. doi: [10.1093/nar/gki816](https://doi.org/10.1093/nar/gki816) PMID: [16129732](https://pubmed.ncbi.nlm.nih.gov/16129732/); PubMed Central PMCID: [PMC1196207](https://pubmed.ncbi.nlm.nih.gov/PMC1196207/).
10. Sassa A, Beard WA, Prasad R, Wilson SH. DNA sequence context effects on the glycosylase activity of human 8-oxoguanine DNA glycosylase. *The Journal of biological chemistry*. 2012; 287(44):36702–10. doi: [10.1074/jbc.M112.397786](https://doi.org/10.1074/jbc.M112.397786) PMID: [22989888](https://pubmed.ncbi.nlm.nih.gov/22989888/); PubMed Central PMCID: [PMC3481274](https://pubmed.ncbi.nlm.nih.gov/PMC3481274/).
11. Budworth H, Matthewman G, O'Neill P, Dianov GL. Repair of tandem base lesions in DNA by human cell extracts generates persisting single-strand breaks. *Journal of molecular biology*. 2005; 351(5):1020–9. doi: [10.1016/j.jmb.2005.06.069](https://doi.org/10.1016/j.jmb.2005.06.069) PMID: [16054643](https://pubmed.ncbi.nlm.nih.gov/16054643/).
12. Harrison L, Hatahet Z, Wallace SS. In vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites. *Journal of molecular biology*. 1999; 290(3):667–84. doi: [10.1006/jmbi.1999.2892](https://doi.org/10.1006/jmbi.1999.2892) PMID: [10395822](https://pubmed.ncbi.nlm.nih.gov/10395822/).

13. David-Cordonnier MH, Boiteux S, O'Neill P. Efficiency of excision of 8-oxo-guanine within DNA clustered damage by XRS5 nuclear extracts and purified human OGG1 protein. *Biochemistry*. 2001; 40(39):11811–8. PMID: [11570881](#).
14. Bellon S, Shikazono N, Cunniffe S, Lomax M, O'Neill P. Processing of thymine glycol in a clustered DNA damage site: mutagenic or cytotoxic. *Nucleic acids research*. 2009; 37(13):4430–40. doi: [10.1093/nar/gkp422](#) PMID: [19468043](#); PubMed Central PMCID: [PMC2715253](#).
15. Pearson CG, Shikazono N, Thacker J, O'Neill P. Enhanced mutagenic potential of 8-oxo-7,8-dihydro-guanine when present within a clustered DNA damage site. *Nucleic acids research*. 2004; 32(1):263–70. doi: [10.1093/nar/gkh150](#) PMID: [14715924](#); PubMed Central PMCID: [PMC373263](#).
16. Malyarchuk S, Brame KL, Youngblood R, Shi R, Harrison L. Two clustered 8-oxo-7,8-dihydroguanine (8-oxodG) lesions increase the point mutation frequency of 8-oxodG, but do not result in double strand breaks or deletions in *Escherichia coli*. *Nucleic acids research*. 2004; 32(19):5721–31. doi: [10.1093/nar/gkh911](#) PMID: [15509868](#); PubMed Central PMCID: [PMC528796](#).
17. Shikazono N, Pearson C, O'Neill P, Thacker J. The roles of specific glycosylases in determining the mutagenic consequences of clustered DNA base damage. *Nucleic acids research*. 2006; 34(13):3722–30. doi: [10.1093/nar/gkl503](#) PMID: [16893955](#); PubMed Central PMCID: [PMC1557791](#).
18. Eccles LJ, Lomax ME, O'Neill P. Hierarchy of lesion processing governs the repair, double-strand break formation and mutability of three-lesion clustered DNA damage. *Nucleic acids research*. 2010; 38(4):1123–34. doi: [10.1093/nar/gkp1070](#) PMID: [19965771](#); PubMed Central PMCID: [PMC2831305](#).
19. Yuan B, Jiang Y, Wang Y, Wang Y. Efficient formation of the tandem thymine glycol/8-oxo-7,8-dihydro-guanine lesion in isolated DNA and the mutagenic and cytotoxic properties of the tandem lesions in *Escherichia coli* cells. *Chemical research in toxicology*. 2010; 23(1):11–9. doi: [10.1021/tx9004264](#) PMID: [20014805](#); PubMed Central PMCID: [PMC2807900](#).
20. Noguchi M, Urushibara A, Yokoya A, O'Neill P, Shikazono N. The mutagenic potential of 8-oxoG/single strand break-containing clusters depends on their relative positions. *Mutation research*. 2012; 732(1–2):34–42. doi: [10.1016/j.mrfmmm.2011.12.009](#) PMID: [22261346](#).
21. Shikazono N, Akamatsu K, Takahashi M, Noguchi M, Urushibara A, O'Neill P, et al. Significance of DNA polymerase I in vivo processing of clustered DNA damage. *Mutation research*. 2013; 749(1–2):9–15. doi: [10.1016/j.mrfmmm.2013.07.010](#) PMID: [23958410](#).
22. Cunniffe S, O'Neill P, Greenberg MM, Lomax ME. Reduced repair capacity of a DNA clustered damage site comprised of 8-oxo-7,8-dihydro-2'-deoxyguanosine and 2-deoxyribonolactone results in an increased mutagenic potential of these lesions. *Mutation research Fundamental and molecular mechanisms of mutagenesis*. 2014; 762:32–9. doi: [10.1016/j.mrfmmm.2014.02.005](#) PMID: [24631220](#); PubMed Central PMCID: [PMC3990186](#).
23. Cunniffe SM, Lomax ME, O'Neill P. An AP site can protect against the mutagenic potential of 8-oxoG when present within a tandem clustered site in *E. coli*. *DNA repair*. 2007; 6(12):1839–49. doi: [10.1016/j.dnarep.2007.07.003](#) PMID: [17704010](#).
24. Kozmin SG, Sedletska Y, Reynaud-Angelin A, Gasparutto D, Sage E. The formation of double-strand breaks at multiply damaged sites is driven by the kinetics of excision/incision at base damage in eukaryotic cells. *Nucleic acids research*. 2009; 37(6):1767–77. doi: [10.1093/nar/gkp010](#) PMID: [19174565](#); PubMed Central PMCID: [PMC2665211](#).
25. Malyarchuk S, Castore R, Harrison L. Apex1 can cleave complex clustered DNA lesions in cells. *DNA repair*. 2009; 8(12):1343–54. doi: [10.1016/j.dnarep.2009.08.008](#) PMID: [19800300](#); PubMed Central PMCID: [PMC2801153](#).
26. Kalam MA, Basu AK. Mutagenesis of 8-oxoguanine adjacent to an abasic site in simian kidney cells: tandem mutations and enhancement of G→T transversions. *Chemical research in toxicology*. 2005; 18(8):1187–92. doi: [10.1021/tx050119r](#) PMID: [16097791](#).
27. Reardon JT, Bessho T, Kung HC, Bolton PH, Sancar A. In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. *Proceedings of the National Academy of Sciences of the United States of America*. 1997; 94(17):9463–8. PMID: [9256505](#); PubMed Central PMCID: [PMC23224](#).
28. Guo J, Hanawalt PC, Spivak G. Comet-FISH with strand-specific probes reveals transcription-coupled repair of 8-oxoGuanine in human cells. *Nucleic acids research*. 2013; 41(16):7700–12. doi: [10.1093/nar/gkt524](#) PMID: [23775797](#); PubMed Central PMCID: [PMC3763531](#).
29. Robins P, Jones CJ, Biggerstaff M, Lindahl T, Wood RD. Complementation of DNA repair in xeroderma pigmentosum group A cell extracts by a protein with affinity for damaged DNA. *The EMBO journal*. 1991; 10(12):3913–21. PMID: [1935910](#); PubMed Central PMCID: [PMC453130](#).
30. Yasui M, Kanemaru Y, Kamoshita N, Suzuki T, Arakawa T, Honma M. Tracing the fates of site-specifically introduced DNA adducts in the human genome. *DNA repair*. 2014; 15:11–20. doi: [10.1016/j.dnarep.2014.01.003](#) PMID: [24559511](#).

31. Grosovsky AJ, Walter BN, Giver CR. DNA-sequence specificity of mutations at the human thymidine kinase locus. *Mutation research*. 1993; 289(2):231–43. PMID: [7690892](#).
32. Arakawa T, Ohta T, Abiko Y, Okayama M, Mizoguchi I, Takuma T. A polymerase chain reaction-based method for constructing a linear vector with site-specific DNA methylation. *Analytical biochemistry*. 2011; 416(2):211–7. doi: [10.1016/j.ab.2011.05.017](#) PMID: [21669180](#).
33. Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F. Efficient gene transfer into the human natural killer cell line, NK1, using the Amaxa nucleofection system. *Journal of immunological methods*. 2004; 284(1–2):133–40. PMID: [14736423](#).
34. Satokata I, Iwai K, Matsuda T, Okada Y, Tanaka K. Genomic characterization of the human DNA excision repair-controlling gene XPAC. *Gene*. 1993; 136(1–2):345–8. PMID: [8294029](#).
35. Sassa A, Caglayan M, Dyrkheeva NS, Beard WA, Wilson SH. Base excision repair of tandem modifications in a methylated CpG dinucleotide. *The Journal of biological chemistry*. 2014; 289(20):13996–4008. doi: [10.1074/jbc.M114.557769](#) PMID: [24695738](#); PubMed Central PMCID: [PMC4022870](#).
36. D'Errico M, Parlanti E, Teson M, de Jesus BM, Degan P, Calcagnile A, et al. New functions of XPC in the protection of human skin cells from oxidative damage. *The EMBO journal*. 2006; 25(18):4305–15. doi: [10.1038/sj.emboj.7601277](#) PMID: [16957781](#); PubMed Central PMCID: [PMC1570445](#).
37. Stevnsner T, Nyaga S, de Souza-Pinto NC, van der Horst GT, Gorgels TG, Hogue BA, et al. Mitochondrial repair of 8-oxoguanine is deficient in Cockayne syndrome group B. *Oncogene*. 2002; 21(57):8675–82. doi: [10.1038/sj.onc.1205994](#) PMID: [12483520](#).
38. de Waard H, de Wit J, Gorgels TG, van den Aardweg G, Andressoo JO, Vermeij M, et al. Cell type-specific hypersensitivity to oxidative damage in CSB and XPA mice. *DNA repair*. 2003; 2(1):13–25. PMID: [12509265](#).
39. Zhang Y, Rohde LH, Wu H. Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. *Current genomics*. 2009; 10(4):250–8. doi: [10.2174/138920209788488544](#) PMID: [19949546](#); PubMed Central PMCID: [PMC2709936](#).
40. Liu M, Doublet S, Wallace SS. Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage. *Mutation research*. 2013; 743–744:4–11. doi: [10.1016/j.mrfmmm.2012.12.003](#) PMID: [23274422](#); PubMed Central PMCID: [PMC3657305](#).
41. Oda Y, Uesugi S, Ikehara M, Nishimura S, Kawase Y, Ishikawa H, et al. NMR studies of a DNA containing 8-hydroxydeoxyguanosine. *Nucleic acids research*. 1991; 19(7):1407–12. PMID: [2027747](#); PubMed Central PMCID: [PMC333893](#).
42. Imoto S, Bransfield LA, Croteau DL, Van Houten B, Greenberg MM. DNA tandem lesion repair by strand displacement synthesis and nucleotide excision repair. *Biochemistry*. 2008; 47(14):4306–16. doi: [10.1021/bi7021427](#) PMID: [18341293](#); PubMed Central PMCID: [PMC2432464](#).
43. Torres-Ramos CA, Johnson RE, Prakash L, Prakash S. Evidence for the involvement of nucleotide excision repair in the removal of abasic sites in yeast. *Molecular and cellular biology*. 2000; 20(10):3522–8. PMID: [10779341](#); PubMed Central PMCID: [PMC85644](#).
44. Fujimoto H, Pinak M, Nemoto T, O'Neill P, Kume E, Saito K, et al. Molecular dynamics simulation of clustered DNA damage sites containing 8-oxoguanine and abasic site. *Journal of computational chemistry*. 2005; 26(8):788–98. doi: [10.1002/jcc.20184](#) PMID: [15806602](#).
45. Itoh M, Hayashi M, Shioda K, Minagawa M, Isa F, Tamagawa K, et al. Neurodegeneration in hereditary nucleotide repair disorders. *Brain & development*. 1999; 21(5):326–33. PMID: [10413020](#).



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

Human DNA methyltransferase gene-transformed yeasts display an inducible flocculation inhibited by 5-aza-2'-deoxycytidine



Kei-ichi Sugiyama*, Makiko Takamune, Hiroko Furusawa, Masamitsu Honma

Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

ARTICLE INFO

Article history:

Received 2 December 2014

Available online 13 December 2014

Keywords:

DNA methyltransferase (DNMT)

5-aza-2'-deoxycytidine (5AZ)

Flocculation

FLO1

ABSTRACT

Mammalian DNA methyltransferases (DNMTs) play an important role in establishing and maintaining the proper regulation of epigenetic information. However, it remains unclear whether mammalian DNMTs can be functionally expressed in yeasts, which probably lack endogenous DNMTs. We cotransformed the budding yeast *Saccharomyces cerevisiae* with the human *DNMT1* gene, which encodes a methylation maintenance enzyme, and the *DNMT3A/3B* genes, which encode *de novo* methylation enzymes, in an expression vector also containing the *GAL1* promoter, which is induced by galactose, and examined the effects of the DNMT inhibitor 5-aza-2'-deoxycytidine (5AZ) on cell growth. Transformed yeast strains grown in galactose- and glucose-containing media showed growth inhibition, and their growth rate was unaffected by 5AZ. Conversely, 5AZ, but not 2'-deoxycytidine, dose-dependently interfered with the flocculation exhibited by *DNMT*-gene transformants grown in glucose-containing medium. Further investigation of the properties of this flocculation indicated that it may be dependent on the expression of a Flocculin-encoding gene, *FLO1*. Taken together, these findings suggest that *DNMT*-gene transformed yeast strains functionally express these enzymes and represent a useful tool for *in vivo* screening for DNMT inhibitors.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

The methylation of DNA, an epigenetic modification, is of central importance for normal cellular development, and changes in DNA methylation may affect the development of cancer [1]. The methylation of cytosine residues in nuclear DNA, a common form of DNA methylation found predominantly in cytosine-phosphate-guanine (CpG) dinucleotides, is an important epigenetic event [2]. Three catalytically active DNA methyltransferases (DNMTs) are involved in the establishment and maintenance of DNA methylation patterns in mammalian cells. DNMT1, which preferentially methylates hemi-methylated DNA, is critical for maintaining DNA methylation patterns [3]. Conversely, DNMT3A and DNMT3B, members of the DNMT3 family of *de novo* DNA methyltransferases, are involved in establishing DNA methylation

patterns during normal embryonic and germ cell development and mainly act on cytosines within unmethylated CpGs [4,5].

5-Aza-2'-deoxycytidine (decitabine; 5AZ), an analog of the natural nucleoside 2'-deoxycytidine, is known to inhibit DNA methylation and is approved for the treatment of myelodysplastic syndrome [6,7]. 5AZ exerts an inhibitory effect on the activity of DNMTs, consequently promoting the reactivation of tumor suppressor genes silenced by DNA methylation [8]. 5AZ taken into cells is phosphorylated and incorporated into the DNA by DNA polymerase [9,10]. Subsequently, DNMTs become trapped by covalently binding to 5AZ, resulting in the depletion of DNMTs [11]. Therefore, generation of the phenotypes associated with 5AZ may facilitate the identification of novel DNMT inhibitors.

In most eukaryotes, DNA methylation occurs exclusively at cytosine residues. Reportedly, 80% of CpG dinucleotides in mammalian genomes are methylated [12]. In contrast, no *DNMT*-like genes are found in the genome of the budding yeast *Saccharomyces cerevisiae*, a model organism for eukaryotic cells [13]. The ease of genetic manipulation of *S. cerevisiae* predisposes it for use as a platform for the functional analysis of mammalian DNMTs. The development of a yeast cell-based system for detecting DNA methylation levels may provide an *in vivo* screening system to identify novel DNMT inhibitors. In this study, we created yeast strains

Abbreviations: 5AZ, 5-aza-2'-deoxycytidine; ACT1, β -actin; CpG, cytosine-phosphate-guanine; DNMT, DNA methyltransferase; OD₆₀₀, optical density at 600 nm; ORF, open reading frame; PCR, polymerase chain reaction; RT-PCR, reverse-transcription polymerase chain reaction.

* Corresponding author. Fax: +81 3 3700 9847.

E-mail address: sugiyama@nihs.go.jp (K.-i. Sugiyama).

transformed with plasmids encoding the human *DNMT1* and *DNMT3A/3B* cDNAs and revealed that these transformants displayed an inducible flocculation phenotype that could be inhibited by 5AZ. Furthermore, we discovered that significantly high mRNA transcript levels of *FLO1*, a Flocculin-encoding gene that causes nonsexual flocculation in yeast [14], are present in the transformants in a glucose-based medium, whereas the upregulation of *FLO1* mRNA is repressed by 5AZ. Here, for the first time, we report the creation of engineered yeasts that have gained the ability to respond to 5AZ.

2. Materials and methods

2.1. Strains, culture conditions, and plasmids

S. cerevisiae YPH250 (*MATa trp1-Δ1 his3-Δ200 leu2-Δ1 lys2-801 ade2-101 ura3-52*) was obtained from the Yeast Genetic Stock Center (University of California at Berkeley, CA, USA). Yeast cells were cultivated at 30 °C in a synthetic medium with a 0.67% yeast nitrogen base containing the appropriate amino acids and carbon sources (final concentration 2%). For 5AZ treatment, yeast cells were incubated with specified amounts of 5AZ. To construct human *DNMT1*, *DNMT3A*, and *DNMT3B* expression plasmids, the open-reading frame (ORF) regions of each gene were amplified by polymerase chain reaction (PCR) and inserted into the multiple cloning site of the expression vectors pYES2/CT or pYES3/CT (Invitrogen, Carlsbad, CA, USA). Construction of the expression plasmids for each *DNMT* proceeded as follows. The *DNMT1* expression plasmid, pY2CThD1, was constructed by cloning a fragment encoding the *DNMT1* ORF, amplified from *DNMT1* cDNA (BC144093), into the pYES2/CT vector by PCR using the primers 5'-CCATCGAT-AAAAAATGCCGCGCGTACCGCCCCAGC-3' and 5'-GGGAATTCCTAGTCTTAGCAGCTTCT-3'. The *DNMT3A* expression plasmid, pY3CThD3A, was constructed by cloning a fragment encoding the *DNMT3A* ORF, amplified from *DNMT3A* cDNA (BC043617), into the pYES3/CT vector by PCR using the primers 5'-CCATCGA-TAAAAAATGCCGCGCATGCCCTCCAGCGG-3' and 5'-GGGAATTC-TTACACACACGCAAAATACT-3'. The *DNMT3B* expression plasmid, pY3CThD3B, was constructed by cloning a fragment encoding the *DNMT3B* ORF, amplified from *DNMT3B* cDNA (BC111933), into the pYES3/CT vector by PCR using the primers 5'-CCATCGA-TAAAAAATGAAGGGAGACACCAGGCATCT-3' and 5'-GGGAATTC-CACATGCAAAGTAGTCTT-3'. The constructed plasmids were verified by DNA sequencing.

2.2. Western blotting analysis

Transformed yeast cells were grown to the late logarithmic phase (approximate optical density at 600 nm [OD_{600}] = 4) in synthetic glucose-containing medium lacking uracil and tryptophan, then the cells were collected by centrifugation, washed, and resuspended at an OD_{600} of 0.4 in synthetic galactose-containing medium supplemented with appropriate requirements. Yeast cells harboring plasmids were cultivated for 0, 16 and 24 h. After centrifugation, cell pellets were rinsed once with 0.9% NaCl. Pellets were suspended in phosphate-buffered saline containing a protease inhibitor cocktail for yeast (Sigma–Aldrich Corporation, St. Louis, MO, USA). The suspension was vortexed with zirconium beads at 4 °C for 5 min, then centrifuged at 3500×g for 10 min to remove cell debris. To examine the expression of *DNMT1*, *DNMT3A*, *DNMT3B*, and β -actin (*ACT1*), we conducted Western blotting analysis using rabbit polyclonal anti-*DNMT1* (ab19905; Abcam, Cambridge, UK), rabbit polyclonal anti-*DNMT3A* (SC-20703; Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA), mouse monoclonal anti-*DNMT3B* (IMG-184A; Imgenex Corporation, San Diego, CA,

USA), and mouse monoclonal anti- β -actin (Abcam) antibodies. β -Actin was used as a loading control. Horseradish peroxidase-conjugated anti-rabbit/mouse Immunoglobulin G antibodies from Jackson ImmunoResearch Labs (West Grove, PA, USA) were used as the secondary antibodies. The signals were visualized using Immunosstar LD (Wako Pure Chemical Industries, Ltd., Osaka, Japan).

2.3. Measurement of growth rate and flocculation

Transformed yeast cells were cultured in synthetic glucose- or galactose-containing minimal medium, with or without 100 μ M 5AZ. Cell growth was monitored by measuring OD_{600} . To measure flocculation ability, culture tubes allowed to settle for 5 min were photographed from beneath and the diameters of both floc (F) and tube (T) were measured. Relative flocculation activity was calculated using the following equation:

$$\text{Relative flocculation activity} = 100 \times (F/T)$$

2.4. Semi-quantitative reverse-transcription polymerase chain reaction

Yeast cells grown to the late logarithmic phase in the glucose-containing medium were harvested. Total RNA was prepared by the glass bead method using an RNeasy Kit (Qiagen N.V., Venlo, Limburg, The Netherlands) with RNase-free DNase treatment, according to the manufacturer's instructions. Total RNA (0.5 μ g) was subjected to reverse-transcription (RT)-PCR using the SuperScript® One-Step RT-PCR System with Platinum® *Taq* DNA Polymerase (Invitrogen). The following primer pairs were used: *FLO1*, 5'-CTCATCGTATATGTTTTGG-3' (forward) and 5'-CGA-TAAACAACCTTCATGG-3' (reverse); *FLO11*, 5'-GTCACGACGGCTAT-TCCAACCACAGTTATTACC-3' (forward) and 5'-GAATACAAGTGGAA-GAGCGAGTAGCAACCAC-3' (reverse); and *ACT1*, 5'-ATTCTGAGGTT-GCTGCTTTGG-3' (forward) and 5'-GAAGATTGAGCAGCGGTTGC-3' (reverse).

2.5. Statistical analysis

Statistical tests comparing multiple groups were performed using one-way analysis of variance followed by Dunnett's *post hoc* test. Data are expressed as means \pm the standard error of the mean.




Fig. 1. Levels of expression of DNA methyltransferases. Cells were grown to the late logarithmic phase (an optical density at 600 nm [OD_{600}] of 3–4) in liquid synthetic glucose-containing medium lacking uracil and tryptophan. Cells were collected by centrifugation, washed, and adjusted to an OD_{600} of 0.4 with synthetic galactose-containing medium lacking uracil and tryptophan. The cells were further cultured for 16 or 24 h. The extracts were prepared and analyzed for DNA methyltransferase (*DNMT*) 1, *DNMT3A*, *DNMT3B*, and β -actin proteins by Western blotting. The results are representative of three independent experiments.

3. Results

3.1. DNA methyltransferase expression in yeast cells

It is thought that DNMT1 acts as a “maintenance” methyltransferase, whereas DNMT3A and DNMT3B act as “*de novo*” enzymes [15,16]. To coexpress human DNMT1 and DNMT3A/3B in yeast cells, the coding regions of DNMTs were placed in expression vectors under the control of the *GAL1* promoter. Yeast cells trans-

formed with the *DNMT1* and *DNMT3A/3B* cDNAs were grown in a synthetic glucose-containing medium to the late logarithmic phase and were subsequently transferred to a synthetic galactose-containing medium to induce DNMT expression. DNMT expression was analyzed by Western blotting using antibodies for each DNMT. As shown in Fig. 1, DNMT1 and DNMT3A/3B were expressed in yeast cells cotransformed with these genes 24 h after induction. This result indicates that DNMT-gene transformants possess the ability to express these DNMTs.




Fig. 2. Phenotypic analysis of transformants. (A and B) Effect of 5-aza-2'-deoxycytidine (5AZ) on the growth of (A) glucose- and (B) galactose-grown transformants. Growth of cells cultured in the presence or absence of 100 μM 5AZ was monitored by measuring optical density at 600 nm (OD_{600}) periodically. Data show the average results of three experiments. (C) Cells were grown to an OD_{600} of 4–6 in glucose- or galactose-containing synthetic dropout liquid medium lacking tryptophan and uracil. Glucose-grown cells cotransformed with pY2hD1 and pY3hD3A/3B flocculate, so that the yeast cells sink to the bottom of the tube. After allowing the yeast to settle for 5 min, flocculation was photographed from the side and underneath. (D) Digital micrographs of glucose-grown transformants. We observed glucose-grown cells to monitor the level of flocculation.




Fig. 3. Effects of 5-aza-2'-deoxycytidine and the natural nucleoside 2dC on the flocculation of glucose-grown transformants. (A and B) Yeast cells treated with 5-aza-2'-deoxycytidine (5AZ; A) and the natural nucleoside 2dC (B) were grown to an optical density at 600 nm (OD_{600}) of 4–7 in glucose-containing synthetic dropout liquid medium lacking tryptophan and uracil. Pictures were taken after allowing the cells to settle at room temperature for 5 min. These experiments were repeated at least three times with similar results, and data from one representative experiment are shown. Histograms show the relative flocculation activity. Data are presented as means \pm standard error of the mean from three independent experiments. Statistical analysis was performed using one-way analysis of variance followed by Dunnett's post hoc test (* $P < .05$; ** $P < .01$; *** $P < .001$ versus control).

3.2. DNMT-gene transformants grown in glucose-based medium exhibit flocculation

To investigate the effects of the induction of DNMT expression, we first checked the growth of the transformants in the absence and presence of 5AZ, a DNMT inhibitor [17]. As shown in Fig. 2A and B, growth rates on glucose- and galactose-containing media were reduced in yeast cells harboring DNMT expression plasmids compared with yeast cells harboring empty vector. Furthermore, 5AZ had no effect on the growth rate of the transformants. These results suggest that the low growth rate of DNMT-gene transformants grown in both galactose- and glucose-containing media is one reason for the expression of DNMTs and that the decrease in the proliferation of these transformants is not reversible by 5AZ.

Reportedly, the tendency of yeast cells to flocculate is related to a growth-arrested phenotype [18]. Because we observed growth inhibition of DNMT-gene transformants in both glucose- and galactose-containing media, we examined the glucose- and galactose-

based culture media of each transformant. Yeast strains harboring DNMT expression plasmids showed flocculation when grown in glucose-containing medium, but were nonflocculent in the galactose-containing medium (Fig. 2C). Furthermore, examination of the flocculating cells by microscopy revealed aggregation of these strains (Fig. 2D). These results indicate that an inducible flocculation phenotype is generated in DNMT-gene transformants grown in glucose-containing media, but not galactose-containing media.

3.3. Flocculation in DNA methyltransferase-gene transformants is repressed by 5-aza-2'-deoxycytidine

Our discovery of an inducible flocculation phenotype in glucose-grown transformants carrying DNMT1 and DNMT3A/3B expression plasmids led us to investigate the effects of 5AZ on this morphogenetic event. In the glucose-containing medium, yeast cells cotransformed with cDNAs encoding DNMT1 and DNMT3A/

3B underwent flocculation, which was significantly suppressed by the addition of 5AZ in a dose-dependent manner. In particular, this flocculation did not occur in the presence of 200 μ M 5AZ. Conversely, the flocculation phenotype conferred resistance to the natural nucleoside 2dC, which has a molecular structure similar to that of 5AZ (Fig. 3). Moreover, 5-azacytidine, a DNMT inhibitor, caused a reduction in flocculation activity similar to that affected by 5AZ in DNMT-gene transformants grown in the glucose-containing medium in a dose-dependent manner (Supplementary Fig. 1). Taken together, these results led us to speculate that cotransformants carrying the DNMT1 and DNMT3A/3B genes functionally express these DNMTs and gain the ability to respond to DNMT inhibition.

3.4. Effect of 5-aza-2'-deoxycytidine on the induction of FLO1 mRNA in DNA methyltransferase-gene transformants

The experimental data in the literature is obtained with YPH250, which is derived from S288C as a reference strain [19]. The FLO8 gene, which encodes a transcriptional activator of the dominant flocculation genes FLO1 and FLO11, harbors a nonsense mutation in S288C [20,21]. To investigate FLO1 and FLO11 mRNA levels in the DNMT-gene transformants, we performed semi-quantitative RT-PCR analysis on total RNA. In these cotransformants (derivatives of S288C), although FLO1 and FLO11 mRNA were detectable, FLO1, but not FLO11, mRNA levels were increased in DNMT-genes transformants (Fig. 4A).

To investigate whether 5AZ affects the level of FLO1 mRNA in DNMT-genes transformants, we analyzed the level of FLO1 mRNA expression. We found that 5AZ (200 μ M) treatment repressed the enhanced level of FLO1 mRNA expression in these transformants (Fig. 4B). Taken together, these results suggest that the inducible flocculation phenotype generated in cotransformants carrying DNMT1 and DNMT3A/3B genes can be induced or repressed by altering the level of FLO1 mRNA expression. Although further experiments are needed to confirm the effect of the level of FLO1 mRNA expression on flocculation, the results presented here suggest that 5AZ affects mRNA expression of the Flocculin-encoding gene, FLO1.

4. Discussion

Although methylation at position 5 of the cytosine moiety catalyzed by DNMT is a heritable epigenetic modification [22], no

DNMT-like genes are believed to exist in the model eukaryote *S. cerevisiae* [13]. In this study, we demonstrated that transformation with the DNMT1 and DNMT3A/3B cDNAs causes yeast cells to acquire a flocculation phenotype that can be inhibited by the DNMT inhibitor, 5AZ [17]. These results suggest that these transformants represent a useful tool for the identification of DNMT inhibitors.

A previous study [23] reported that 5AZ has no effect on the growth rate of yeast expressing mouse DNMT1 or DNMT3A and that the presence of both enzymes affected no fundamental properties of yeasts. However, our findings indicate that yeast cotransformants carrying the DNMT1 and DNMT3A/3B genes experienced growth inhibition and exhibited inducible flocculation (Fig. 2). One possible explanation for this discrepancy is that these two apparently different phenotypes are linked to the background genome of each strain; therefore, the strain used in this study may represent a good model for the study of DNMT function *in vivo*. We speculate that exogenously expressed DNMTs will affect the regulation of cellular growth and/or metabolism in the yeast strain YPH250.

Although GAL1 gene expression in *S. cerevisiae* is repressed in the glucose-based medium [24], our results indicate that 5AZ inhibits an inducible flocculation phenotype in DNMT-gene transformants grown in the synthetic glucose-containing medium. This implies that this flocculation is caused by expression of DNMTs. This observation is consistent with a previous report [25] that states that the GAL1 promoter causes leaky expression in glucose-based media. Furthermore, transformants with low levels of DNMTs seem to be more sensitive to DNMT inhibitors, suggesting that the glucose-induced promotion of flocculation is useful for the detection of novel DNMT inhibitors.

We showed that glucose-grown cells cotransformed with cDNAs encoding DNMT1 and DNMT3A/3B displayed an inducible flocculation phenotype inhibited by 5AZ and that the FLO1 gene, which encodes a cell-surface Flocculin [26], was upregulated in these cells compared with control cells (transformed with empty vector; Figs. 3A and 4A). These results suggest that the inducible flocculation is coordinated by FLO1, the expression of which is regulated through DNMT-mediated epigenetic effects on the FLO1 promoter. Indeed, the epigenetic modifying agent 5AZ (a DNMT inhibitor) inhibited the induction of mRNA encoding FLO1 in cotransformants (Fig. 4B). 5AZ incorporated into genomic DNA exerts DNMT inhibitory activity through covalent adduct formation with DNMTs, triggering proteasome-mediated degradation [17,27]. Therefore, it is also possible to state that DNMTs function-




Fig. 4. mRNA levels of flocculation genes in glucose-grown transformants. (A) Yeast cells were grown to an optical density at 600 nm (OD_{600}) of 4–7 in glucose-containing synthetic dropout liquid medium lacking tryptophan and uracil. Total RNA was extracted from transformants, and mRNA levels of FLO1, FLO11, and β -actin (ACT1) were monitored by semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR). The results are representative of three independent experiments. (B) Yeast cells were treated with the indicated concentration of 5-aza-2'-deoxycytidine for 40 h. Total RNA was extracted from the transformants, and mRNA levels of FLO1 and ACT1 were monitored by semi-quantitative RT-PCR. The results are representative of three independent experiments.

ally expressed in the nuclei of transformants display a 5AZ-inhibitable behavior, namely flocculation. We are now working to analyze the methylation level in the promoter region of the *FLO1* gene to characterize the epigenetic alterations of yeast transformants carrying the *DNMT1* and *DNMT3A/3B* genes.

Further experiments involving the identification of yeast CpG site methylation by heterogeneous DNMTs and the analysis of the relationship between histone modification and DNA methylation will help us to understand the principles of epigenetic modification in *S. cerevisiae*.

Acknowledgments

This research was supported by Division of Genetics and Mutagenesis, NIH Grants.

The authors wish to thank Tsukasa Fukamachi and Kazuhisa Nakajima for their excellent technical assistance.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2014.12.032>.

References

- [1] S.B. Baylin, P.A. Jones, A decade of exploring the cancer epigenome—biological and translational implications, *Nat. Rev. Cancer* 11 (2011) 726–734.
- [2] A. Bird, DNA methylation patterns and epigenetic memory, *Genes Dev.* 16 (2002) 6–21.
- [3] H. Denis, F. Fuks, Regulation of mammalian DNA methyltransferases: a route to new mechanisms, *EMBO Rep.* 12 (2011) 647–656.
- [4] E. Li, Chromatin modification and epigenetic reprogramming in mammalian development, *Nat. Rev. Genet.* 3 (2002) 662–673.
- [5] M. Okano, D.W. Bell, D.A. Haber, E. Li, DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development, *Cell* 99 (1999) 247–257.
- [6] E. Jabbour, J.P. Issa, G. Garcia-Manero, H. Kantarjian, Evolution of decitabine development, *Cancer* 112 (2008) 2341–2351.
- [7] H. Kantarjian, J.P.J. Issa, C.S. Rosenfeld, J.M. Bennett, M. Albitar, J. DiPersio, V. Klimek, J. Slack, C. de Castro, F. Ravandi, Decitabine improves patient outcomes in myelodysplastic syndromes, *Cancer* 106 (2006) 1794–1803.
- [8] M. Daskalakis, T.T. Nguyen, C. Nguyen, P. Guldborg, G. Köhler, P. Wijermans, P.A. Jones, M. Lübbert, Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment, *Blood* 100 (2002) 2957–2964.
- [9] J. Bouchard, R. Momparler, Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase, *Mol. Pharmacol.* 24 (1983) 109–114.
- [10] P.A. Jones, S.M. Taylor, Cellular differentiation, cytidine analogs and DNA methylation, *Cell* 20 (1980) 85–93.
- [11] Y. Sauntharajah, D. Lavelle, J. DeSimone, DNA hypo-methylating agents and sickle cell disease, *Br. J. Haematol.* 126 (2004) 629–636.
- [12] S. Maegawa, G. Hinkal, H.S. Kim, L. Shen, L. Zhang, J. Zhang, N. Zhang, S. Liang, L.A. Donehower, J.-P.J. Issa, Widespread and tissue specific age-related DNA methylation changes in mice, *Genome Res.* 20 (2010) 332–340.
- [13] M.M. Suzuki, A. Bird, DNA methylation landscapes: provocative insights from epigenomics, *Nat. Rev. Genet.* 9 (2008) 465–476.
- [14] A. Teunissen, H. Steensma, The dominant flocculation genes of *Saccharomyces cerevisiae* constitute a new subtelomeric gene family, *Yeast* 11 (1995) 1001–1013.
- [15] G. Egger, S. Jeong, S.G. Escobar, C.C. Cortez, T.W. Li, Y. Saito, C.B. Yoo, P.A. Jones, G. Liang, Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival, *Proc. Natl. Acad. Sci. U.S.A.* 103 (2006) 14080–14085.
- [16] M. Okano, S. Takebayashi, K. Okumura, E. Li, Assignment of cytosine-5 DNA methyltransferases Dnmt3a and Dnmt3b to mouse chromosome bands 12A2–A3 and 2H1 by in situ hybridization, *Cytogenet. Cell Genet.* 86 (1999) 333–334.
- [17] J.K. Christman, 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy, *Oncogene* 21 (2002) 5483–5495.
- [18] S.E. Van Mulders, E. Christianen, S.M. Saerens, L. Daenen, P.J. Verbelen, R. Willaert, K.J. Verstrepen, F.R. Delvaux, Phenotypic diversity of Flo protein family-mediated adhesion in *Saccharomyces cerevisiae*, *FEMS Yeast Res.* 9 (2009) 178–190.
- [19] R.S. Sikorski, P. Hieter, A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*, *Genetics* 122 (1989) 19–27.
- [20] O. Kobayashi, H. Suda, T. Ohtani, H. Sone, Molecular cloning and analysis of the dominant flocculation gene *FLO8* from *Saccharomyces cerevisiae*, *Mol. Gen. Genet.* 251 (1996) 707–715.
- [21] H. Liu, C.A. Styles, G.R. Fink, *Saccharomyces cerevisiae* S288C has a mutation in *FLO8*, a gene required for filamentous growth, *Genetics* 144 (1996) 967–978.
- [22] K.D. Robertson, DNA methylation and human disease, *Nat. Rev. Genet.* 6 (2005) 597–610.
- [23] U. Bulkowska, T. Ishikawa, A. Kurlandzka, J. Trzcinska-Danielewicz, R. Derlacz, J. Fronk, Expression of murine DNA methyltransferases Dnmt1 and Dnmt3a in the yeast *Saccharomyces cerevisiae*, *Yeast* 24 (2007) 871–882.
- [24] J.S. Flick, M. Johnston, Two systems of glucose repression of the *GAL1* promoter in *Saccharomyces cerevisiae*, *Mol. Cell. Biol.* 10 (1990) 4757–4769.
- [25] V. Meyer, M. Arentshorst, S.J. Flitter, B.M. Nitsche, M.J. Kwon, C.G. Reynaga-Pena, S. Bartnicki-Garcia, C.A. van den Hondel, A.F. Ram, Reconstruction of signaling networks regulating fungal morphogenesis by transcriptomics, *Eukaryot. Cell* 8 (2009) 1677–1691.
- [26] L. Fichtner, F. Schulze, G.H. Braus, Differential Flo8p-dependent regulation of *FLO1* and *FLO11* for cell–cell and cell–substrate adherence of *S. cerevisiae* S288c, *Mol. Microbiol.* 66 (2007) 1276–1289.
- [27] C. Stressemann, F. Lyko, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, *Int. J. Cancer* 123 (2008) 8–13.

Article

Comprehensive DNA Adduct Analysis Reveals Pulmonary Inflammatory Response Contributes to Genotoxic Action of Magnetite Nanoparticles

Kousuke Ishino ¹, Tatsuya Kato ¹, Mamoru Kato ², Tatsuhiko Shibata ², Masatoshi Watanabe ³, Keiji Wakabayashi ⁴, Hitoshi Nakagama ¹ and Yukari Totsuka ^{1,*}

¹ Division of Carcinogenesis and Prevention, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan; E-Mails: kishino@ncc.go.jp (K.I.); takatou1311@gmail.com (T.K.); hnakagam@ncc.go.jp (H.N.)

² Division of Cancer Genomics, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan; E-Mails: mamkato@ncc.go.jp (M.K.); tashibat@ncc.go.jp (T.S.)

³ Division of Materials Science and Engineering, Graduate School of Engineering, Yokohama National University, Hodogaya-ku, Yokohama 240-8501, Japan; E-Mail: mawata@ynu.ac.jp

⁴ Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, 52-1, Yada, Shizuoka 422-8526, Japan; E-Mail: kwakabayashi@u-shizuoka-ken.ac.jp

* Author to whom correspondence should be addressed; E-Mail: ytotsuka@ncc.go.jp; Tel.: +81-3-3542-2511 (ext. 4552); Fax: +81-3-3542-2530.

Academic Editor: James C. Bonner

Received: 11 October 2014 / Accepted: 30 January 2015 / Published: 4 February 2015

Abstract: Nanosized-magnetite (MGT) is widely utilized in medicinal and industrial fields; however, its toxicological properties are not well documented. In our previous report, MGT showed genotoxicity in both *in vitro* and *in vivo* assay systems, and it was suggested that inflammatory responses exist behind the genotoxicity. To further clarify mechanisms underlying the genotoxicity, a comprehensive DNA adduct (DNA adductome) analysis was conducted using DNA samples derived from the lungs of mice exposed to MGT. In total, 30 and 42 types of DNA adducts were detected in the vehicle control and MGT-treated groups, respectively. Principal component analysis (PCA) against a subset of DNA adducts was applied and several adducts, which are deduced to be formed by inflammation or oxidative stress, as the case of etheno-deoxycytidine (ϵ dC), revealed higher contributions to MGT exposure. By quantitative-LC-MS/MS analysis, ϵ dC levels